Company news
Lexaria Bioscience Corp. news in 2022
Lexaria Bioscience Corp.'s news releases, calls and decks from 2022, newest first.
Lexaria Receives First Granted Patent in Canada
December 28, 2022
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
December 20, 2022
Lexaria’s Human Oral Nicotine Study Begins Dosing
December 19, 2022
Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program
November 28, 2022
Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies
November 20, 2022
Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes
November 7, 2022
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
October 31, 2022
Lexaria's Human Clinical Hypertension Study a Success
October 26, 2022
Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors
September 1, 2022
Lexaria Receives New Patent in Mexico
August 30, 2022
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
August 9, 2022
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
July 26, 2022
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 25, 2022
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
July 13, 2022
Lexaria's Human Nicotine Study Nearing Start Date
July 12, 2022
Lexaria Signs Manufacturing and License Agreements with BevNology
June 20, 2022
Lexaria Grants License to AnodGen Bioceuticals
June 7, 2022
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
June 5, 2022
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
June 2, 2022
Lexaria Grants License to Valcon Medical for the European Market
June 1, 2022
Lexaria Announces 2022 Annual Meeting Results
May 31, 2022
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
April 20, 2022
Lexaria Commences Multi-Week Human Clinical Hypertension Study
April 18, 2022
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
April 13, 2022
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
April 11, 2022
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
April 10, 2022
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
March 14, 2022
Lexaria Granted Important New Oral Nicotine Patent
March 7, 2022
Lexaria Provides Annual Letter From the CEO
January 26, 2022